GB226

BIOLOGICAL5 trials

Sponsors

Genor Biopharma Co., Ltd.

Conditions

Alveolar Soft Part SarcomaB-cell Non-Hodgkin's LymphomaCervical CancerMetastatic Non-small Cell Lung CancerPeripheral T Cell Lymphoma

Phase 1

Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

Genor Biopharma Co., Ltd.Metastatic Non-small Cell Lung Cancer

Start: 2019-07-23End: 2022-12-31Target: 42Updated: 2021-03-03

Phase 2

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Genor Biopharma Co., Ltd.Peripheral T Cell Lymphoma

Start: 2018-07-02End: 2022-12-30Target: 86Updated: 2021-03-03

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Genor Biopharma Co., Ltd.Alveolar Soft Part Sarcoma

Start: 2018-09-06End: 2022-12-30Target: 35Updated: 2021-03-03

Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)

Genor Biopharma Co., Ltd.B-cell Non-Hodgkin's Lymphoma

Start: 2018-10-15End: 2022-12-30Target: 53Updated: 2021-03-03

A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive

Genor Biopharma Co., Ltd.Cervical Cancer

Start: 2019-05-23End: 2022-07-31Target: 80Updated: 2021-03-03

Related Papers

<i>JAK3</i> <sup>A573V</sup> and <i>JAK3</i> <sup>M511I</sup> mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway

Journal for ImmunoTherapy of Cancer2025-04-015 citations

Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).

2023-06-08

A multicenter, open-label, single-arm, phase II trial to evaluate the efficacy and safety of geptanolimab (GB226) in the treatment of patients (pts) with programmed cell death ligand 1 (PD-L1)–positive recurrent or metastatic cervical cancer, for whom prior platinum-containing chemotherapy has failed.

Journal of Clinical Oncology2023-06-011 citations

Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Journal of Hematology & Oncology2021-01-1262 citations

Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study

Clinical Cancer Research2020-10-1241 citations

Abstract CT041: The efficacy and safety of Geptanolimab (GB226) in patients with relapsed/refractory peripheral T cell lymphoma (PTCL): A multicenter, open-label, single-arm, phase 2 trial

Cancer Research2020-08-15